re: 7-1 f/s, AS increase,
8K 11/21/12, http://www.sec.gov/Archives/edgar/data/1510775/000121390012006442/f8k111612_tgapothecary.htm
Item 5.07: Submission of Matters to a Vote of Security Holders
On November 16, 2012, we received written consent from our company’s board of directors and a holder of 57.47% of our company’s voting securities to effect a stock split of our issued and outstanding shares of common stock, to a name change, and to increase our company’s authorized capital.
Pursuant to Section 78.320 of the Nevada Revised Statues, any action required or permitted to be taken at a meeting of the stockholders may be taken without a meeting if a written consent to such action is signed by stockholders holding at least a majority of the voting power and on November 16, 2012, we received written consent from a holder of 57.47% of our voting securities, for a name change to “Biologix Hair Inc.”, and to effect a forward split of our company’s issued and outstanding shares on a basis of seven (7) new for one (1) old. Upon effect of the forward split, our issued and outstanding shares of common stock shall increase from 8,700,000 to 60,900,000 shares of common stock, with a par value of $0.001.
The board of directors and stockholders also approved to increase our company’s authorized capital from 100,000,000 to 900,000,000 shares of common stock, with a par value of $0.001.
These amendments are currently under review with the Financial Industry Regulatory Authority (“FINRA”). We will announce the completion of FINRA review and the effectiveness of these changes on the market by filing a Current Report on Form 8-K.